COVID-19 INFEKSIYASINI O‘TKAZGAN REVMATOID ARTRITLI BEMORLARDA KLINIK VA IMMUNOLOGIK O‘ZGARISHLAR
Article Sidebar
Main Article Content
Аннотация:
Ushbu tezisda COVID-19 infeksiyasini o‘tkazgan revmatoid artritli bemorlarda kasallikning klinik va immunologik kechish xususiyatlari yoritildi. Tadqiqotga EULAR/ACR 2010 mezonlariga mos 120 nafar revmatoid artritli bemor kiritildi: 60 nafari COVID-19 o‘tkazgan asosiy guruhni, 60 nafari COVID-19 o‘tkazmagan nazorat guruhini tashkil etdi. COVID-19 o‘tkazgan bemorlarda ertalabki qotishish ko‘proq uchradi va uzoqroq davom etdi, subfebril harorat, mialgiya, plevrit yoki perikardit, interstitsial o‘pka shikastlanishi kabi belgilar nisbatan yuqori qayd etildi. Shuningdek, C-reaktiv oqsil, IL-6, IL-17 va TGF-b1 ko‘rsatkichlarining oshishi hamda rentgenologik o‘zgarishlarning ko‘proq uchrashi aniqlandi.
Article Details
Как цитировать:
Библиографические ссылки:
Belov B.S., Muravyova N.V., Tarasova G.M. COVID-19: rheumatological aspects. Effective Pharmacotherapy. 2020;16(16):18-25. doi:10.33978/2307-3586-2020-16-16-18-25.
Nasonov E.L. Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: results and prospects. Scientific and Practical Rheumatology. 2024;62(1):32-54. doi:10.47360/1995-4484-2024-32-54.
Akhmedov H.S. Features of the immune status in rheumatoid arthritis depending on the climatic, geographical and ecological zones of Uzbekistan. Scientific and Practical Rheumatology. 2016;54(2):183-186. doi:10.14412/1995-4484-2016-183-186.
Jin L., Gan J., Li X., Lu Y., Wang Y., Wong V.K.W. Rheumatoid arthritis and COVID-19 outcomes: a systematic review and meta-analysis. BMC Rheumatology. 2024;8(1):61. doi:10.1186/s41927-024-00431-5.
Vladulescu-Trandafir A.-I., Bojinca V.-C., Munteanu C., et al. Rheumatoid arthritis and COVID-19 at the intersection of immunology and infectious diseases: a related PRISMA systematic literature review. International Journal of Molecular Sciences. 2024;25(20):11149. doi:10.3390/ijms252011149.
Kishimoto T. IL-6: from arthritis to CAR-T-cell therapy and COVID-19. International Immunology. 2021;33(10):515-519. doi:10.1093/intimm/dxab011.